Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ADC Therapeutics SA

Get SEC filing alerts via email and in your feed for ADC Therapeutics SA

ADCT

ADC Therapeutics SA

About ADC Therapeutics SA

ADC Therapeutics SA is a pioneering biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment. Its flagship product, ZYNLONTA, targets CD19 for relapsed or refractory B-cell lymphomas and has received multiple regulatory approvals. The company is expanding its pipeline with innovative ADCs for solid tumors and hematologic malignancies, leveraging strategic partnerships to enhance global access and address significant unmet medical needs in oncology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ADC Therapeutics SA

1
1
ADC Therapeutics SA ADC Therapeutics Reports Q1 2026 Financial Results with $20.9M Revenue and $33M Net Loss

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ADC Therapeutics SA ADC Therapeutics SA Reports 14.9% Revenue Growth and Focus on ZYNLONTA Expansion

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ADC Therapeutics SA ADC Therapeutics Reports Q3 2025 Financial Results with $16.4M Revenue and $41M Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ADC Therapeutics SA ADC Therapeutics Reports 8.2% Revenue Growth but Increases Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ADC Therapeutics SA ADC Therapeutics Reports 27.6% Revenue Growth in Q1 2025, Net Loss Decreases

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ADC Therapeutics SA ADC Therapeutics Reports $157.8 Million Net Loss for 2024, Revenue Increases to $70.8 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ADC Therapeutics SA ADC Therapeutics Reports 27.4% Revenue Growth, Improved Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments